ALCLS Fundamental Analysis - CELLECTIS

Fundamental Rating

Overall ALCLS gets a fundamental rating of 2 out of 10. We evaluated ALCLS against 81 industry peers in the Biotechnology industry. Both the profitability and financial health of ALCLS have multiple concerns. ALCLS is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALCLS has reported negative net income.

ALCLS had a negative operating cash flow in the past year.

In the past 5 years ALCLS always reported negative net income.

In the past 5 years ALCLS reported 4 times negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -28.30%, ALCLS perfoms like the industry average, outperforming 51.85% of the companies in the same industry.

ALCLS has a Return On Equity of -103.16%. This is comparable to the rest of the industry: ALCLS outperforms 48.15% of its industry peers.

		Industry Rank	Sector Rank
ROA	-28.3%
ROE	-103.16%
ROIC	N/A

ROA(3y)-26.82%

ROA(5y)-25.52%

ROE(3y)-79.12%

ROE(5y)-63.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 3.66%, ALCLS is doing worse than 61.73% of the companies in the same industry.

The Profit Margin and Operating Margin are not available for ALCLS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	3.66%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALCLS does not have a ROIC to compare to the WACC, probably because it is not profitable.

ALCLS has more shares outstanding than it did 1 year ago.

ALCLS has more shares outstanding than it did 5 years ago.

The debt/assets ratio for ALCLS has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -0.24, we must say that ALCLS is in the distress zone and has some risk of bankruptcy.

ALCLS's Altman-Z score of -0.24 is in line compared to the rest of the industry. ALCLS outperforms 50.62% of its industry peers.

ALCLS has a Debt/Equity ratio of 0.91. This is a neutral value indicating ALCLS is somewhat dependend on debt financing.

The Debt to Equity ratio of ALCLS (0.91) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.91
Debt/FCF	N/A
Altman-Z	-0.24

ROIC/WACCN/A

WACC6.69%

2.3 Liquidity

ALCLS has a Current Ratio of 1.38. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.

ALCLS has a worse Current ratio (1.38) than 64.20% of its industry peers.

A Quick Ratio of 1.38 indicates that ALCLS should not have too much problems paying its short term obligations.

ALCLS has a Quick ratio of 1.38. This is comparable to the rest of the industry: ALCLS outperforms 40.74% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.38
Quick Ratio	1.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.80% over the past year.

Looking at the last year, ALCLS shows a very strong growth in Revenue. The Revenue has grown by 154.92%.

The Revenue has been growing by 16.44% on average over the past years. This is quite good.

EPS 1Y (TTM)70.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%104.35%

Revenue 1Y (TTM)154.92%

Revenue growth 3Y8.44%

Revenue growth 5Y16.44%

Sales Q2Q%105.89%

3.2 Future

Based on estimates for the next years, ALCLS will show a very negative growth in Earnings Per Share. The EPS will decrease by -54.16% on average per year.

The Revenue is expected to grow by 25.15% on average over the next years. This is a very strong growth

EPS Next Y-166.15%

EPS Next 2Y-83.7%

EPS Next 3Y-54.16%

EPS Next 5YN/A

Revenue Next Year45.52%

Revenue Next 2Y32.52%

Revenue Next 3Y9.94%

Revenue Next 5Y25.15%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALCLS. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALCLS. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ALCLS's earnings are expected to decrease with -54.16% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-83.7%

EPS Next 3Y-54.16%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALCLS!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

CELLECTIS

EPA:ALCLS (1/2/2026, 7:00:00 PM)

4.215

+0.02 (+0.48%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-07 2025-11-07/amc

Earnings (Next)03-11 2026-03-11/amc

Inst Owners15.56%

Inst Owner ChangeN/A

Ins Owners2.82%

Ins Owner ChangeN/A

Market Cap422.87M

Revenue(TTM)112.63M

Net Income(TTM)-100.18M

Analysts84.62

Price Target6.63 (57.3%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)14.93%

Min EPS beat(2)4.37%

Max EPS beat(2)25.48%

EPS beat(4)4

Avg EPS beat(4)48.46%

Min EPS beat(4)4.37%

Max EPS beat(4)145.69%

EPS beat(8)7

Avg EPS beat(8)30.86%

EPS beat(12)9

Avg EPS beat(12)22.27%

EPS beat(16)12

Avg EPS beat(16)21.56%

Revenue beat(2)1

Avg Revenue beat(2)21.17%

Min Revenue beat(2)-20.05%

Max Revenue beat(2)62.39%

Revenue beat(4)3

Avg Revenue beat(4)64.94%

Min Revenue beat(4)-20.05%

Max Revenue beat(4)161.56%

Revenue beat(8)5

Avg Revenue beat(8)33.5%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)15.22%

EPS NY rev (3m)15.22%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)50.74%

Revenue NY rev (3m)50.74%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	5.31
P/FCF	N/A
P/OCF	N/A
P/B	5.12
P/tB	5.18
EV/EBITDA	N/A

EPS(TTM)-0.28

EYN/A

EPS(NY)-1.01

Fwd EYN/A

FCF(TTM)-0.31

FCFYN/A

OCF(TTM)-0.28

OCFYN/A

SpS0.79

BVpS0.82

TBVpS0.81

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-28.3%
ROE	-103.16%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	3.66%
FCFM	N/A

ROA(3y)-26.82%

ROA(5y)-25.52%

ROE(3y)-79.12%

ROE(5y)-63.67%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.26

Health

		Industry Rank	Sector Rank
Debt/Equity	0.91
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	16.04%
Cap/Sales	3.51%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.38
Quick Ratio	1.38
Altman-Z	-0.24

F-Score3

WACC6.69%

ROIC/WACCN/A

Cap/Depr(3y)12.8%

Cap/Depr(5y)139.39%

Cap/Sales(3y)9.66%

Cap/Sales(5y)33.81%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)70.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%104.35%

EPS Next Y-166.15%

EPS Next 2Y-83.7%

EPS Next 3Y-54.16%

EPS Next 5YN/A

Revenue 1Y (TTM)154.92%

Revenue growth 3Y8.44%

Revenue growth 5Y16.44%

Sales Q2Q%105.89%

Revenue Next Year45.52%

Revenue Next 2Y32.52%

Revenue Next 3Y9.94%

Revenue Next 5Y25.15%

EBIT growth 1Y46.16%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-5.42%

EBIT Next 3Y-33.24%

EBIT Next 5Y-29.24%

FCF growth 1Y51.3%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y55.32%

OCF growth 3YN/A

OCF growth 5YN/A

CELLECTIS / ALCLS.PA FAQ

Can you provide the ChartMill fundamental rating for CELLECTIS?

ChartMill assigns a fundamental rating of 2 / 10 to ALCLS.PA.

What is the valuation status of CELLECTIS (ALCLS.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to CELLECTIS (ALCLS.PA). This can be considered as Overvalued.

What is the profitability of ALCLS stock?

CELLECTIS (ALCLS.PA) has a profitability rating of 1 / 10.

Can you provide the financial health for ALCLS stock?

The financial health rating of CELLECTIS (ALCLS.PA) is 2 / 10.

What is the expected EPS growth for CELLECTIS (ALCLS.PA) stock?

The Earnings per Share (EPS) of CELLECTIS (ALCLS.PA) is expected to decline by -166.15% in the next year.

CELLECTIS (ALCLS.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

CELLECTIS / ALCLS.PA FAQ

Can you provide the ChartMill fundamental rating for CELLECTIS?

What is the valuation status of CELLECTIS (ALCLS.PA) stock?

What is the profitability of ALCLS stock?

Can you provide the financial health for ALCLS stock?

What is the expected EPS growth for CELLECTIS (ALCLS.PA) stock?